The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes

Diabetic Medicine

Volumn 20, Issue 7, 2003, Pages 586-593

  Scuffham, Paul ^a   Carr, L ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

CSII; Economic evaluation; IDDM; Insulin pumps; Quality of life

Indexed keywords

INSULIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MONTE CARLO METHOD; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MULTIVARIATE ANALYSIS; PATIENT SATISFACTION; QUALITY OF LIFE;

EID: 0037660876     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00991.x     Document Type: Article

References (28)

1. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002; 18: S14-S20.
2. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Int Med 2001; 161: 2293-2300.
3. Pickup J, Mattlock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: a meta-analysis of randomised controlled trials. Br Med J 2002; 324: 705-708.
4. Data Pro. Williamstown MA: TreeAge Software Inc., 2002.
5. Rubin AL. Diabetes for Dummies. New York: Hungry Minds, 1999.
6. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001; 24: 430-434.
7. Muhlhauser I, Sawicki PT, Blank M, Overmann H, Bender R, Berger M. Prognosis of persons with type 1 diabetes on intensified insulin therapy in relation to nephropathy. J Intern Med 2000; 248: 333-341.
8. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of diabetes interventions and complications (EDIC). Diabetes Care 2002; 22: 99-111.
9. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-1784.
10. Pickup J, Keen H. Continuous subcutaneous insulin infusion in type 1 diabetes. Br Med J 2001; 322: 1262-1263.
11. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996; 19: 324-327.
12. Rudolph JW, Hirsch IB. An assessment of insulin pump therapy in an academic diabetes clinic. (Conference Abstract) Diabetes 2000; 49 (Suppl. 1): 501.
13. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W et al. Incidence of severe hypoglycaemia requiring emergency treatment in Type 1 and Type 2 diabetes: a population-based study of health service resource use. Diabet Med 2002; 19 (Suppl. 2): 12-13.
14. Department of Health. NHS Reference Costs 2001. London: Department of Health, 2002.
15. Netten A, Rees T, Harrison G. Unit Costs of Health and Social Care 2001. Canterbury: Personal Social Services Research Unit, University of Kent, 2002.
16. Davis J. Insulin Pump Therapy (INPUT). Lymington, Hants: INPUT, 2001.
17. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). Online 42, 2001. Clinical and Biomedical Computing Ltd, 2002. www.bnf.org.uk.
18. National Health Service England and Wales. Drug Tariff, March edn. London: The Stationary Office, 2002.
19. National Institute for Clinical Excellence. Technical Guidance for Manufacturers and Sponsors on Making a Submission to a Technology Appraisal. London: National Institute for Clinical Excellence, 2001.
20. Smith DH, Gravelle H. The practice of discounting in economic evaluations of health care interventions. Int J Health Tech Ass 2001; 17: 236-243.
21. Carins J. Discounting in economic evaluation. In Drummond MF, McGuire A eds. Economic Evaluation in Health Care. Oxford: Oxford University Press, 2001; 236-255.
22. Smith DH, Gravelle H. The Practice of Discounting Economic Evaluation in Health Care Technology, CHE Technical Paper Series 19. York: University of York, Centre for Health Economics, 1999.
23. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford: Oxford University Press, 1997.
24. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years. Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
25. Raftery J. NICE: Faster access to modern medicine? Analysis of guidance on health technologies. Br Med J 2001; 323: 1300-1303.
26. Sanfield JA, Hegstad M, Hanna RS. Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality. Diabetes Educ 2002; 28: 599-607.
27. American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes Care 2000; 23: S90.
28. Bell DS, Ovalle F. Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy. Endocr Pract 2000; 6: 357-360.